Alto Neuroscience Inc. has announced the upcoming initiation of a Phase 2b clinical trial for their drug ALTO-207, expected to start by mid-2026. ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to achieve rapid antidepressant effects in patients with treatment-resistant depression $(TRD.UK)$ while mitigating adverse events associated with pramipexole alone. This trial follows the publication of results from the PAX-D study in The Lancet Psychiatry, which demonstrated significant symptom reduction in TRD patients using pramipexole, though accompanied by a high rate of adverse effects. Alto plans to collaborate with the National Health Service and PAX-D clinical sites for the trial. The study results have already been presented during an investor conference call by Alto Neuroscience.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。